Katherine Tang

Katherine Tang is a Principal Scientist in Toxicology at Crinetics Pharmaceuticals since September 2024. Prior experience includes positions as Principal Scientist in Drug Safety Research & Evaluation at Takeda from April 2023 to July 2024, and Senior Scientist in Toxicology at Turning Point Therapeutics from June 2021 to February 2023. At Bristol Myers Squibb, Katherine held several roles from November 2019 to June 2021, including Senior Scientist and multiple Scientist positions in Discovery Toxicology. Previous experience also includes roles at Celgene, Hoffmann-La Roche, Amicus Therapeutics, and the University of Medicine & Dentistry of New Jersey, covering areas from Exploratory Toxicology to Discovery Biology. Katherine Tang holds a Bachelor of Science in Microbiology from the University of Michigan and a Master of Science in Biomedical Sciences from Rutgers University.